|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Don't ignore a big shift for American Express and don't dig in your heels, says Jim Cramer.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today acknowledged the receipt of a Congressional letter and reaffirmed its commitment to discovering and developing treatments for patients with rare cancers with the...
Senator Bernie Sanders (I-VT) and Representative Elijah Cummings (D-MD) sent a letter to Ariad Pharmaceuticals (ARIA) today questioning the company's drug pricing.
Why Trump is killing biotech stocks, the Shire-for-Radius rumor makes no sense and Bernie Sanders gets a tweeting lesson.
Do that if you like top ticking crowd favorites, but set a protective stop.
Ariad (ARIA) stock was under pressure on Friday after Bernie Sanders rebuked the company's drug pricing practices.
Cramer is avoiding TPC Composites and is lukewarm on Kinder Morgan.
Consistency and discipline are two values this market has sorely lacked in 2016, Cramer says.
Ariad Pharmaceuticals' Iclusig now costs patients nearly $199,000 per year.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Leerink started coverage of Ariad Pharmaceuticals (ARIA) stock with an 'outperform' rating on Monday.
Ariad Pharma (ARIA) stock closed higher on Tuesday given renewed speculation that it might be a buyout target.
After putting in a bottom, Ariad Pharmaceuticals (ARIA) stock 'has risen like a Phoenix from the ashes,' said TheStreet's Chris Versace and Bob Lang.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced it has completed the rolling submission of the New Drug Application (NDA) for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to...
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Morgan Stanley Global Healthcare Conference being held in New York City.
The company's share price despite reporting better-than-expected earnings and revenue and
ARIAD (ARIA) stock is jumping in afternoon trading today after the company reported better-than-expected results for the second quarter before Thursday's market open.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter and first half of 2016, including revenue from sales of Iclusig ® (ponatinib).
Stocks with insider trader activity include SKUL, EA and ARIA
Chipotle, Wendy's on the bull side and gold stocks on the bear side.
Here's a technical look at how to trade five stocks trading for less than $10 a share that are headed for breakouts.
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2016 financial results on Thursday, July 28, 2016, before the market opens.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its Annual Meeting of Stockholders will be webcast live on July 21, 2016 and can be accessed by visiting the investor relations section of the Company's...
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "dead cat bounce" (down big yesterday but up big today) candidate
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the completion of its strategic review and its plans for future growth and vision to become a leader in the discovery, development and commercialization of...
ARIAD Pharmaceuticals, Inc. (ARIAD; NASDAQ:ARIA) today announced that it has completed two distribution agreements for Iclusig ® (ponatinib) outside of the United States.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the initiation of a New Drug Application (NDA) submission for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the U.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced long-term follow-up data from its pivotal Phase 2 PACE clinical trial of Iclusig ® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated...
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.